F5, Inc. R&D increased by 7.0% to $151.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $136.56M to $151.04M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 1.3% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $133.28M | $124.70M | $130.27M | $135.84M | $138.74M | $138.52M | $142.32M | $141.36M | $128.77M | $127.83M | $119.58M | $122.21M | $124.39M | $123.95M | $130.52M | $136.56M | $136.35M | $136.39M | $141.16M | $151.04M |
| QoQ Change | — | -6.4% | +4.5% | +4.3% | +2.1% | -0.2% | +2.7% | -0.7% | -8.9% | -0.7% | -6.5% | +2.2% | +1.8% | -0.4% | +5.3% | +4.6% | -0.2% | +0.0% | +3.5% | +7.0% |
| YoY Change | — | — | — | — | +4.1% | +11.1% | +9.3% | +4.1% | -7.2% | -7.7% | -16.0% | -13.6% | -3.4% | -3.0% | +9.2% | +11.7% | +9.6% | +10.0% | +8.2% | +10.6% |